P

Priothera SAS

16 employees

Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Medical
Pharmaceutical

Date founded

2020

Funding rounds raised

Total raised

$35M

from 4 investors over 4 rounds

P

Priothera SAS raised $20M on February 23, 2022

Investors: European Investment Bank

P

Priothera SAS raised $35M on October 12, 2020

Investors: Earlybird Venture Capital, Tekla Capital Management and HealthCap

FAQ